Document
PGR2025-00057, No. 2026 Exhibit - Arun K Ghosh and David D Anderson, Tetrahydrofuran, Tetrahydropyran, Triazoles and Related Heterocyclic Derivatives as Hiv Protease Inhibitors, Future M...
Cite Document
PGR2025-00057, No. 2026 Exhibit - Arun K Ghosh and David D Anderson, Tetrahydrofuran, Tetrahydropyran, Triazoles and Related Heterocyclic Derivatives as Hiv Protease Inhibitors, Future Med Chem 2011,
+ More Snippets
Document
PGR2025-00057, No. 2015 Exhibit - Alexander S Harmata, et al, Bridged bicyclic building block upgrading Photochemical synthesis of bicyclo311heptan 1 amines, Willard Henry Dow Laboratory,...
Cite Document
PGR2025-00057, No. 2015 Exhibit - Alexander S Harmata, et al, Bridged bicyclic building block upgrading Photochemical synthesis of bicyclo311heptan 1 amines, Willard Henry Dow Laboratory, Dept of Chem
+ More Snippets
Document
PGR2025-00057, No. 2008 Exhibit - Juan J Rojas and James A Bull, Oxetanes in Drug Discovery Campaigns, Journal of Medicinal Chemistry 2023, 66 , 12697 12709 (P.T.A.B. Oct. 8, 2025)
Cite Document
PGR2025-00057, No. 2008 Exhibit - Juan J Rojas and James A Bull, Oxetanes in Drug Discovery Campaigns, Journal of Medicinal Chemistry 2023, 66 , 12697 12709 (P.T.A.B. Oct. 8, 2025)
+ More Snippets
Document
PGR2025-00057, No. 2016 Exhibit - Jang Won Son and Soo Lim, Glucagon Like Peptide 1 Based Therapies A New Horizon in Obesity Management, Endocrinology and Metabolism 2024, 39, 206...
Cite Document
PGR2025-00057, No. 2016 Exhibit - Jang Won Son and Soo Lim, Glucagon Like Peptide 1 Based Therapies A New Horizon in Obesity Management, Endocrinology and Metabolism 2024, 39, 206 221 (P.T.A.B. Oct. 8
+ More Snippets
Document
PGR2025-00057, No. 2012 Exhibit - Edon Vitaku, et al, Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among US FDA Approved Pharmaceut...
Cite Document
PGR2025-00057, No. 2012 Exhibit - Edon Vitaku, et al, Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among US FDA Approved Pharmaceuticals, Journal
+ More Snippets
Document
PGR2025-00057, No. 2018 Exhibit - A Study of Orforlipron LY3502970 in Adult Participants with Obesity or Overweight With Weight Related Comorbidities ATTAIN 1, Lilly Trials (P.T.A.B. Oct. 8, 2...
Cite Document
PGR2025-00057, No. 2018 Exhibit - A Study of Orforlipron LY3502970 in Adult Participants with Obesity or Overweight With Weight Related Comorbidities ATTAIN 1, Lilly Trials (P.T.A.B. Oct. 8, 2025)
+ More Snippets
Document
PGR2025-00057, No. 2027 Exhibit - Seung Hwa Kwak et al, Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition, Jou...
Cite Document
PGR2025-00057, No. 2027 Exhibit - Seung Hwa Kwak et al, Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition, Journal of Medicinal
+ More Snippets
Document
PGR2025-00057, No. 2001 Exhibit - Declaration of Geoffrey D Biegler Pursuant to 37 CFR § 4210c2 (P.T.A.B. Jul. 18, 2025)
Cite Document
PGR2025-00057, No. 2001 Exhibit - Declaration of Geoffrey D Biegler Pursuant to 37 CFR § 4210c2 (P.T.A.B. Jul. 18, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1006 Exhibit - Chinese Patent Application No 2023113726059 “Su II” (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1006 Exhibit - Chinese Patent Application No 2023113726059 “Su II” (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1013 Exhibit - Chinese Patent Application No 202311371725 “the ’725 Provisional” (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1013 Exhibit - Chinese Patent Application No 202311371725 “the ’725 Provisional” (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1020 Exhibit - Chinese Patent Application No 202311582240 “the ’240 Provisional” (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1020 Exhibit - Chinese Patent Application No 202311582240 “the ’240 Provisional” (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1012 Exhibit - Frias, et al, Lancet, 40210400472–483 2023 (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1012 Exhibit - Frias, et al, Lancet, 40210400472–483 2023 (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1004 Exhibit - Kawai, et al, Proc Natl Acad Sci U S A, 1174729959 29967 2020 (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1004 Exhibit - Kawai, et al, Proc Natl Acad Sci U S A, 1174729959 29967 2020 (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1007 Exhibit - Certified English Translation of Chinese Patent App No 202311372609 (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1007 Exhibit - Certified English Translation of Chinese Patent App No 202311372609 (P.T.A.B. Jun. 20, 2025)
+ More Snippets
Document
PGR2025-00057, No. 1010 Exhibit - Liu, et al, Expert Opinion on Therapeutic Patents, 3010781 794 2020 (P.T.A.B. Jun. 20, 2025)
Cite Document
PGR2025-00057, No. 1010 Exhibit - Liu, et al, Expert Opinion on Therapeutic Patents, 3010781 794 2020 (P.T.A.B. Jun. 20, 2025)
+ More Snippets